The following randomized, double-masked pivotal trials were conducted for the 4 LUCENTIS indications: wAMD: MARINA–Phase III, multicenter, 2-year, sham injection-controlled study; primary end point at 1 year. ANCHOR–Phase III, multicenter, 2-year, active treatment-controlled study; primary end point at 1 year. PIER–Phase IIIb, 2-year, sham injection-controlled study; primary end point at 1 year. HARBOR–Phase III, multicenter, 2-year, active treatment-controlled dose-response study; primary end point at 1 year. RVO: BRAVO–Phase III, multicenter, 1-year, sham injection-controlled study; primary end point at 6 months. CRUISE–Phase III, multicenter, 1-year, sham injection-controlled study; primary end point at 6 months. DME and DR in Patients with DME: RISE–Phase III, multicenter, 3-year, sham injection-controlled study; primary end point at 2 years. RIDE–Phase III, long-term, 3-year, sham injection-controlled study; primary end point at 2 years. 1-8

Resources

Resources for your patients.

LUCENTIS Direct

Simple, personalized ordering.

LUCENTIS Co-pay Card Program

Support for your patients with commercial insurance.

LUCENTIS Access Solutions

Access and reimbursement services for your patients.